Publication: Panobinostat and Multiple Myeloma in 2018
Open/View Files
Date
2018
Authors
Published Version
Journal Title
Journal ISSN
Volume Title
Publisher
AlphaMed Press
The Harvard community has made this article openly available. Please share how this access benefits you.
Citation
Yee, Andrew J., and Noopur S. Raje. 2018. “Panobinostat and Multiple Myeloma in 2018.” The Oncologist 23 (5): 516-517. doi:10.1634/theoncologist.2017-0644. http://dx.doi.org/10.1634/theoncologist.2017-0644.
Research Data
Abstract
FDA and EMA approval of panobinostat offers an additional therapeutic option for multiple myeloma; however, adoption of panobinostat has been limited by its adverse event profile. Trials are ongoing to optimize the dosing of panobinostat and to identify its best partners, in order to fully realize the potential of this drug class.
Description
Other Available Sources
Keywords
Terms of Use
This article is made available under the terms and conditions applicable to Other Posted Material (LAA), as set forth at Terms of Service